Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Prelude Therapeutics (PRLD)
NASDAQ:PRLD
Holding PRLD?
Track your performance easily
PRLD Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.66 - $6.80
Previous Close$2.6
Volume602.34K
Average Volume (3M)231.09K
Market Cap
$143.06M
Enterprise Value-$18.58M
Total Cash (Recent Filing)$179.84M
Total Debt (Recent Filing)$18.20M
Price to Earnings (P/E)―
Beta1.40
Next Earnings
Nov 12, 2024EPS Estimate
-$0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.93
Shares Outstanding55,024,470
10 Day Avg. Volume640,065
30 Day Avg. Volume231,093
Standard Deviation0.27
R-Squared0.07
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)0.64
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.14
Forecast
1Y Price Target
$4.75Price Target Upside93.88% Upside
Rating ConsensusHold
Number of Analyst Covering4
Prelude Therapeutics News
PremiumCompany Announcements
Prelude Therapeutics Unveils Promising Cancer Treatment Data at ESMO
PremiumCompany Announcements
Prelude Therapeutics Unveils Strategic Insights for Investors
Bulls Say, Bears Say
Bulls Say
Clinical TrialsPrelude intends to initiate a combo trial of PRT3789 + Keytruda (pembrolizumab) based on in vivo studies that show enhanced anti-tumor activity.
Financial PerformanceWith encouraging PRT3789 monotherapy data in SMARCA2 LOF mutants, three assets advancing through the clinic, and a cash position of $179.8MM, Prelude shares continue to represent an attractive investment opportunity.
Safety ProfilePRT3789 was generally well-tolerated, with no drug-related SAEs or dose-limiting toxicities to date.
Bears Say
Analyst RatingAnalyst downgrades PRLD to Underweight from Equal Weight based upon a lack of near-to-mid-term high-impact catalysts.
Investor InterestLimited investor interest is expected, leading to no significant potential upside to the stock heading into or on the data update.
Stock PerformanceThe stock dipped by almost 43%—vs. a 2.2% increase in the value of the XBI benchmark.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
PRLD FAQ
What was Prelude Therapeutics’s price range in the past 12 months?
Prelude Therapeutics lowest stock price was $1.66 and its highest was $6.80 in the past 12 months.
What is Prelude Therapeutics’s market cap?
Currently, no data Available
When is Prelude Therapeutics’s upcoming earnings report date?
Prelude Therapeutics’s upcoming earnings report date is Nov 12, 2024 which is in 54 days.
How were Prelude Therapeutics’s earnings last quarter?
Prelude Therapeutics released its earnings results on Aug 12, 2024. The company reported -$0.46 earnings per share for the quarter, missing the consensus estimate of -$0.43 by -$0.03.
Is Prelude Therapeutics overvalued?
According to Wall Street analysts Prelude Therapeutics’s price is currently Undervalued.
Does Prelude Therapeutics pay dividends?
Prelude Therapeutics does not currently pay dividends.
What is Prelude Therapeutics’s EPS estimate?
Prelude Therapeutics’s EPS estimate is -$0.47.
How many shares outstanding does Prelude Therapeutics have?
Prelude Therapeutics has 42,174,210 shares outstanding.
What happened to Prelude Therapeutics’s price movement after its last earnings report?
Prelude Therapeutics reported an EPS of -$0.46 in its last earnings report, missing expectations of -$0.43. Following the earnings report the stock price went down -6.863%.
Which hedge fund is a major shareholder of Prelude Therapeutics?
Among the largest hedge funds holding Prelude Therapeutics’s share is Baker Bros Advisors LP. It holds Prelude Therapeutics’s shares valued at 39M.
---
Prelude Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$4.75 (93.88% Upside)
$4.75 (93.88% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-18.23%
12-Months-Change
Fundamentals
Return on Equity
-58.45%
Trailing 12-Months
Asset Growth
-20.07%
Trailing 12-Months
Company Description
Prelude Therapeutics
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet need.
---
PRLD Stock 12 Month Forecast
Average Price Target
$4.75
▲(93.88% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Precision BioSciences
―
Fate Therapeutics
―
Gritstone Oncology
―
Best Analysts Covering PRLD
1 Year
1 Year Success Rate
4/6 ratings generated profit
1 Year Average Return
+10.02%
reiterated a sell rating 6 days ago
Copying Jeffrey Hung's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +10.02% per trade.
---